TissueNetix is developing the next generation cardiac liability assay for drug discovery and development.
TissueNetix is a startup life sciences company whose goal is to develop assay kits for chemical toxicity screening using human cells. The first product will be an assay to better predict cardiac liability side effects for drug discovery. The current standard cellular assay is poorly predictive of the potential of a drug to have cardiac liabilities. A more predictive assay is needed. The target market is companies involved in drug discovery.